The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …

Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

Background Ixazomib is an oral proteasome inhibitor that is currently being studied for the
treatment of multiple myeloma. Methods In this double-blind, placebo-controlled, phase 3 …

Chemotherapy-induced thrombocytopenia (CIT) is a common complication of the treatment
of non-hematologic malignancies. Many patient-related variables (eg, age, tumor type …

Background The proteasome inhibitor bortezomib was initially approved for the treatment of
relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for …

Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the
treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase …

Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed,
and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the …

Proteasome inhibition has emerged as an important therapeutic strategy in multiple
myeloma (MM). Since the publication of the first phase 1 trials of bortezomib 10 years ago …

Answer questions and earn CME/CNE Advances in genomics and molecular biology have
identified aberrant proteins in cancer cells that are attractive targets for cancer therapy …

Thrombocytopenia is a common problem in cancer patients. Aside from bleeding risk,
thrombocytopenia limits chemotherapy dose and frequency. In evaluating thrombocytopenic …